The significance of clinically defined subgroups of Alzheimer's disease
Chui, H.C.
Journal of Neural Transmission. Supplementum 24: 57-68
1987
ISSN/ISBN: 0303-6995 PMID: 3316501 Document Number: 301064
The significance of clinically defined subgroups of Alzheimer's disease (AD) is discussed within a framework of etiologic, pathogenetic, and treatment issues. Cerebral amyloid angiopathy and familial AD are proposed as etiologic subtypes. Clinical heterogeneity associated with age at onset and sex are thought to reflect the presence of secondary pathogenetic factors. Longitudinal studies are necessary to clarify the meaning of various symptomatic patterns.
Document emailed within 1 workday
Related Documents
Baker, F.M.; Wiley, C.; Kokmen, E.; Chandra, V.; Schoenberg, B.S. 1999: Delirium episodes during the course of clinically diagnosed Alzheimer's disease Journal of the National Medical Association 91(11): 625-630Gillen, T.E.; Gregg, K.M.; Yuan, H.; Kurth, M.C.; Krishnan, K.R. 2001: Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease Psychopharmacology Bulletin 35(2): 83-96
Solomon, A.; Weiss, D.T. 1987: Serologically defined V region subgroups of human lambda light chains Journal of Immunology 139(3): 824-830
Brotman, D.J.; Eberhart, C.G.; Burger, P.C.; McArthur, J.C.; Hellmann, D.B. 2000: Primary angiitis of the central nervous system and Alzheimer's disease: clinically and pathologically evident in a single patient Journal of Rheumatology 27(12): 2935-2937
Abraham, C.R.; Bem Meir, A.; Tempst, P. 1990: Facile and sensitive assay for monitoring proteolytic activities with defined specificities: studies on amyloid beta-protein processing in Alzheimer's disease Peptide Research 3(5): 211-215
Preuss, U.W.; Frodl-Bauch, T.; Benda, E.; Soyka, M.; Möller, H.; Hegerl, U. 1999: Late auditory evoked potentials (P300) do not discriminate between subgroups of alcohol-dependent patients defined by family history and antisocial personality traits European Journal of Medical Research 4(3): 114-120
Mackell, J.A.; Ferris, S.H.; Mohs, R.; Schneider, L.; Galasko, D.; Whitehouse, P.; Schmitt, F.; Sano, M.; Thal, L.J. 1997: Multicenter evaluation of new instruments for Alzheimer's disease clinical trials: summary of results. The Alzheimer's Disease Cooperative Study Alzheimer Disease and Associated Disorders 11 Suppl. 2: S65-S69
Flores-Río de la Loza, L.J.; Ordóñez-Lozano, G.; Pineda-Olvera, B. 2005: Determination of systemic infections due to Mycoplasma in patients with clinically defined amyotrophic lateral sclerosis Revista de Neurologia 41(5): 262-267
Fukatsu, R.; Tsuzuki, K.; Hayashi, Y.; Takamaru, Y.; Sasaki, N.; Yoshida, T.; Hatakeyama, Y.; Fuji, N.; Takahata, N. 1997: Recent advances in Alzheimer's disease research--amyloid precursor protein trafficking, processing, and mutations in Alzheimer's disease linked genes Hokkaido Journal of Medical Science 72(1): 3-11
Morris, J.C.; Edland, S.; Clark, C.; Galasko, D.; Koss, E.; Mohs, R.; van Belle, G.; Fillenbaum, G.; Heyman, A. 1993: The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease Neurology 43(12): 2457-2465
Morris, J.C.; Mohs, R.C.; Rogers, H.; Fillenbaum, G.; Heyman, A. 1988: Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease Psychopharmacology Bulletin 24(4): 641-652
Miyakawa, T. 1988: Brain pathology in Alzheimer's disease. Ultrastructure of amyloid fibrils in Alzheimer's disease and Down's syndrome Nihon Rinsho. Japanese Journal of Clinical Medicine 46(7): 1471-1474
Szpak, G.M.; Lechowicz, W.; Lewandowska, E.; Bertrand, E.; Wierzba-Bobrowicz, T.; Gwiazda, E.; Schmidt-Sidor, B.; Dymecki, J. 2001: Neurones and microglia in central nervous system immune response to degenerative processes. Part 1: Alzheimer's disease and Lewy body variant of Alzheimer's disease. Quantitative study Folia Neuropathologica 39(3): 181-192
Bufill, E.; Blesa, R. 2006: Alzheimer's disease and brain evolution: is Alzheimer's disease an example of antagonistic pleiotropy? Revista de Neurologia 42(1): 25-33
Tang, X.; Yin, C.; Zhang, F.; Fu, Y.; Chen, W.; Chen, Y.; Wang, J.; Jia, W.; Xu, A. 2003: Measurement of subgroups of peripheral blood T lymphocytes in patients with severe acute respiratory syndrome and its clinical significance Chinese Medical Journal 116(6): 827-830
Fărcăşel, L. 1988: Current data on the anatomy and physiopathology of Alzheimer's disease (Alzheimer-type senile dementia--ATSD) Revista Medico-Chirurgicala A Societatii de Medici Si Naturalisti Din Iasi 92(2): 289-292
Ng, H.K. 1994: Alzheimer's disease and Alzheimer-type of cerebral degenerations in Chinese Clinical and Experimental Neurology 31: 85-98
DE Felice, F.G.; Houzel, J-Christophe.; Garcia-Abreu, Jé.; Louzada, P.Roberto.F.; Afonso, R.C.; Meirelles, M.Nazareth.L.; Lent, R.; Neto, V.Moura.; Ferreira, Sérgio.T. 2001: Inhibition of Alzheimer's disease β-amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer's therapy FASEB Journal 15(7): 1297-1299
Narindrasorasak, S.; Altman, R.A.; Gonzalez-DeWhitt, P.; Greenberg, B.D.; Kisilevsky, R. 1995: An interaction between basement membrane and Alzheimer amyloid precursor proteins suggests a role in the pathogenesis of Alzheimer's disease Laboratory Investigation; A Journal of Technical Methods and Pathology 72(3): 272-282
Schoch, C.; Schnittger, S.; Kern, W.; Dugas, M.; Hiddemann, W.; Haferlach, T. 2003: Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid leukemia Haematologica 88(3): 351-352